Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Rituximab Use in Pediatric Central Demyelinating Disease.
Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects.
Prospective memory, emotional valence, and multiple sclerosis.
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Oxidative modification of serum proteins in multiple sclerosis.
Microglia activation is associated with IFN-α induced depressive-like behavior.
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Imaging outcomes for trials of remyelination in multiple sclerosis.
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
First proof for rituximab in IgG4-related disease
Multiple sclerosis: an immune or neurodegenerative disorder?
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Reactive astrocytes as therapeutic targets for CNS disorders.
Colestipol May Quickly Eliminate Teriflunomide
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability

Pages